Zanfina Ademi: Routine Lp(a) Testing as a Cost-Effective Step Toward Precision Cardiovascular Prevention
FH Europe Foundation shared an insightful post from Professor Zanfina Ademi on LinkedIn:
“Lp(a): A Missed Opportunity in Cardiovascular Prevention
Despite its strong genetic link to ASCVD and its prevalence in 1 in 5 people, Lp(a) raemains under-tested in clinical practice. A new study in Atherosclerosis highlights both the clinical relevance and cost-effectiveness of routine Lp(a) testing, strengthening the case for its integration into cardiovascular risk assessment.
Led by Monash University, supported by global experts and initiated by FH Europe Foundation, the study shows:
- Routine Lp(a) testing is cost-saving across multiple health systems
- It enables earlier intervention with existing therapies
- It supports value-based care and equitable access to precision prevention
The findings align with the Brussels International Declaration, a 2025 global policy initiative urging governments to include Lp(a) in national cardiovascular screening programs.
Prof. Zanfina Ademi, senior author and health economist at Monash: “From both a public health and economic standpoint, this is a highly cost-effective intervention targeting a major gap in cardiovascular prevention.”

Stay updated with Hemostasis Today.
-
Mar 16, 2026, 14:52Gianluca Franceschini: The Difference in Breast Cancer is Made by the Team
-
Mar 16, 2026, 14:51Heghine Khachatryan: Hematologic Causes of Cryptogenic Stroke
-
Mar 16, 2026, 14:35Simon Senanu: Understanding the Extrinsic Coagulation Pathway
-
Mar 16, 2026, 14:27Mahesan Subramaniam: Why Messy Spaces Impact Women’s Stress Levels More Than Men’s
-
Mar 16, 2026, 14:21Marlies Alvarenga: Balancing the Scales in Women’s Cardiovascular Health
-
Mar 16, 2026, 13:32Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
-
Mar 16, 2026, 13:12Mariia Kumskova։ New Insights Into Platelet Dysfunction in Ehlers-Danlos Syndrome
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope